Phaseline

Companies › Fate Therapeutics

Fate Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FT819
allogeneic CAR-T cells targeting CD19
CD19Phase 2Lupus Nephritis; Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Lymphoma, B-CellSep 2027
FT836
NK cell engager
–Phase 1Non-Small Cell Lung CancerJan 2028
FT839
CAR-T cell therapy targeting CD4+ T cells
–Phase 1ANCA-Associated Vasculitis (AAV)Oct 2028
FT825
HER2-directed CAR-T cell therapy
ERBB2Phase 1Advanced Solid TumorMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06308978FT819Phase 1Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)ImmunologySep 2027
NCT07216105FT836Phase 1Non-Small Cell Lung CancerOncologyJan 2028
NCT07800871FT839Phase 1ANCA-Associated Vasculitis (AAV)ImmunologyOct 2028
NCT06241456FT825Phase 1Advanced Solid TumorOncologyMay 2029
NCT07570862FT819Phase 2Lupus NephritisImmunologyJul 2029
NCT04629729FT819Phase 1Lymphoma, B-CellOncologySep 2039

From the company's SEC filings

Cash and short-term investments of $139m on 2026-09-30; operating cash outflow about $110m a year; runway about 15 months at that burn, to Jan 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics AstraZeneca Miltenyi Biomedicine Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical

Companies built like this

Miltenyi Biomedicine Shanghai Ming Ju Biotechnology Allogene Therapeutics Replimune Lyell Immunopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.